Evidence map›Paper›PMID 38649217›Full record

ReviewAdvances in kidney disease and health2024

Renal Replacement Therapy in Cirrhosis: A Contemporary Review.

Caterina Pelusio, Paul Endres, Javier A Neyra, Andrew S Allegretti

Open access · greenAbstract readReview
In one paragraph

Review in Advances in kidney disease and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Treating Hepatorenal Syndrome in the Current Era.Journal of the American Society of Nephrology : JASN · 2026
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Caterina PelusioDepartment of Health Sciences, Section of Anesthesiology and Intensive Care, University of Florence, Florence, Italy; Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Paul EndresSidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.
Javier A NeyraDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Andrew S AllegrettiDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA. Electronic address: aallegretti@mgh.harvard.edu.
University of Alabama at Birmingham · USMassachusetts General Hospital · USThomas Jefferson University · US

Funding

UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3M
Artificial Intelligence to Predict Outcomes in Patients with Acute Kidney Injury on Continuous Renal Replacement TherapyR01DK133539 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Girish Nitin Nadkarni, Javier A. Neyra · 2023 to 2026
$2.6M
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention TrialR01DK128208 · NIDDK · TUFTS MEDICAL CENTER · PI DREW, DAVID ALAN, NEYRA, JAVIER A. · 2021 to 2025
$1.6M
Personalizing Therapies for Acute Kidney Injury in CirrhosisK23DK128567 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Andrew S Allegretti · 2022 to 2026
$982k
NIDDK NIH HHS K23 DK128567NIDDK NIH HHS P30 DK079337NIDDK NIH HHS R01 DK128208NIDDK NIH HHS R01 DK133539
6 · The paper itself

Abstract

Acute kidney injury is a common complication of decompensated cirrhosis, frequently requires hospitalization, and carries a high short-term mortality. This population experiences several characteristic types of acute kidney injury: hypovolemic-mediated (prerenal), ischemic/nephrotoxic-mediated (acute-tubular necrosis), and hepatorenal syndrome. Prerenal acute kidney injury is treated with volume resuscitation. Acute-tubular necrosis is treated by optimizing perfusion pressure and discontinuing the offending agent. Hepatorenal syndrome, a unique physiology of decreased effective arterial circulation leading to renal vasoconstriction and ultimately acute kidney injury, is treated with plasma expansion with albumin and splanchnic vasoconstrictors such as terlipressin or norepinephrine. Common acute stressors such as bleeding, infection, and volume depletion often contribute to multifactorial acute kidney injury. Even with optimal medical management, many clinicians are faced with the challenge of initiating renal replacement therapy in these patients. This article reviews the epidemiology, indications, and complex considerations of renal replacement therapy for acute kidney injury in decompensated cirrhosis.

Indexed as

Acute Kidney InjuryHepatorenal SyndromeLiver CirrhosisRenal Replacement TherapyHumansAcute kidney injuryDialysisHepatorenal SyndromeLiver failure

Identifiers

PMID38649217
PMCPMC11103613
OpenAlexW4394987562

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.